Omega Speedmaster Legend
Children's Hospital of Philadelphia Gene Therapy Spinout Spark Therapeutics Hauls In $72.8 Million Omega Seamaster Navy
Raise Over $100 Million, Plans To Consolidate Pharma Biz
This press release contains "forward looking statements" concerning the development of Complexa's products, the potential benefits and attributes of such products, and Complexa's expectations regarding its prospects. Forward looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of Omega Speedmaster White Dial
Company President and CEO Josh Tarnoff added, "We're delighted to have JAFCO join the Complexa investor base. The JAFCO team has a long history of being very supportive of its funded companies. They bring highly valued contributions to Complexa."
Bay Area's Twist Bioscience Secures $31.1 Million NeoStem, Inc. Accesses $30 Million Equity Facility With Aspire Capital
the date of this press release. Actual results may vary. Complexa undertakes no obligation to update any forward looking statements for any reason.
Mike Beyer, 773 463 4211Help employers find you! Check out all the .
KemPharm, Inc. Bags $60 Million VC Firm Epidarex Capital Unveils 47.5 Fund For Early Stage UK Startups, Spinouts
Earlier this month, Complexa announced that it began Phase I trials for the treatment of acute kidney injury related to the administration of contrast imaging agents in high risk patients, CXA 10's proof of concept indication. This Phase I trial is designed to assess CXA 10's safety and pharmacokinetics. Through the use of various biomarkers, the study will also demonstrate CXA 10's mechanism of action and document target organ engagement that will further illuminate its regulation of critical inflammatory pathways.
Sam Brown Inc.
Complexa Wraps Up 13 Million Series B Financing Round
PITTSBURGH (BUSINESS WIRE) Complexa, Inc., a clinical stage platform anti inflammatory and fibrotic disease focused biopharmaceutical company, announced today that it has completed a $13 Omega Speedmaster Legend million dollar Series B financing. The company will use funds raised to further advance clinical development of two formulations of its lead compound CXA 10. The first is an intravenous formulation which is currently in Phase I clinical trials for a form of acute kidney disease and the second is an oral formulation for a form of chronic kidney disease for which an IND will be filed later this year. JAFCO Life Science Investment, a part of JAFCO Co., Ltd. ("JAFCO") led the financing round with significant participation from existing investors. There is great interest from large pharmaceutical companies in this type of novel human pathway signaling technology and a large underserved patient population facing the life threatening inflammatory based diseases that Complexa is studying."
Redwood City Biotech ARMO BioSciences Locks Down $30 Million Series B OXiGENE (OXGN) Announces $16 Million At The Market Registered Direct Offering
Complexa, Inc. is a clinical stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The company's proprietary technology involves the synthesis and therapeutic applications of endogenous nitro fatty acids (NFAs) and additional structure/function related mediators that are designed to treat various diseases. Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa's technologies act to amplify the existing anti inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease.
Retrophin, Inc. (RTRX) Signs A $80 Million Term Loan And Convertible Note Issuing
CXA 10 and related drug candidates in Complexa's portfolio utilize the body's own endogenous signaling pathways to promote defense and repair responses, which can be applied to a number of underserved, life threatening inflammatory based diseases. Complexa continues its work on oral chronic treatments, and development programs in other inflammatory, neurodegenerative and fibrotic related therapeutic categories are also under active evaluation.
San Francisco Biotech Startup Nurix Taps $25.1 Million Financing Jubilant Pharma To Omega Seamaster Professional 300m Black
Complexa, Inc. Completes $13 Million Series B Financing to Further Advance Clinical Development of CXA 10
Omega Speedmaster Legend
Nike Max Thea Mens
Copyright 2006–2007 Phoenix Gallery. All rights reserved. Site design by . . . || mccallum design